Companies To Watch

  1. Companies To Watch: Provention Bio
    5/1/2019

    This 15-person virtual biotech is trying to stop immune-mediated disease early, before it becomes a chronic condition.

  2. Companies To Watch: Vyome Therapeutics
    4/1/2019

    Vyome Therapeutics has built platforms and is developing products that address antibiotic resistance in severe skin conditions.

  3. Companies To Watch: Azitra
    3/1/2019

    Azitra is a small, young, early-stage company developing microbial biotherapeutics for conditions arising on the skin that can be addressed by using the microbiome.

  4. Companies-To-Watch 2018 Annual Roundup
    3/1/2019

    At the end of every year since we began the monthly column, Companies to Watch, I have gone back to the featured companies and asked each one to send me a short assessment of its progress since it appeared in Life Science Leader.

  5. Companies to Watch —Where Are They Now?
    2/1/2019

    Since launching our Companies To Watch section in 2012 we have covered more than 50 companies. This year we plan to periodically look back at some of them and see where they are today. 

  6. Companies To Watch: Synspira
    1/2/2019

    Synspira is developing glycopolymer drugs for infection, inflammation, and congestion in the lungs. According CEO Shenda Baker, “We would like to see more companies in this space. But we are also looking forward to leading the way.”

  7. Companies To Watch: Athersys
    11/7/2018

    Athersys is mass-producing off-the-shelf stem cells for multiple conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.

  8. Companies To Watch: Symbiotix Biotherapies
    10/4/2018

    Symbiotix Biotherapies is an early pioneer of the microbiome space, preparing to enter clinical-stage development of its lead compound for treating MS and IBD.

  9. Companies To Watch: United Neuroscience
    9/3/2018

    “We are a vaccine company,” says CEO Mei Mei Hu. “We’re developing a new class of vaccines for endogenous proteins, leveraging a commercially successful technology platform in which we’ve invested more than 20 years.”

  10. Companies To Watch: Acceleron
    8/2/2018

    Acceleron has four drugs in development in the hematology, neuromuscular, and pulmonary disease areas. Its lead drug luspatercept has completed Phase 3 trials for treating myelodysplastic syndromes (MDS).